CRC

June 13, 2022
‘Unprecedented’ 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly Bookmark
George Lundberg, MD
In a remarkable new study, covered in this article from The ASCO Post, 100% of 14 previously untreated patients with mismatch repair-deficient rectal cancer had complete responses—that is, no more signs of their cancer—after treatment with the checkpoint-inhibitor drug dostarlimab (brand name Jemperli) in a phase 2 clinical trial.

.
June 13, 2022
Colon Cancer Treatment & Management Bookmark
George Lundberg, MD
Written for physicians and healthcare professionals, Medscape provides this trustworthy, encyclopedic resource for treating and managing metastatic colorectal cancer.

.
June 13, 2022
Latest Evidence on Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: A 2022 Update Bookmark
George Lundberg, MD

This scientific research paper from Critical Reviews in Oncology/Hematology discusses current options for treatments known as immune checkpoint inhibitors for people with advanced colorectal cancer.

.